The anti-apoptotic BCL-2 protein family, comprising members like BCL-2, BCL-XL, and MCL-1, has emerged as highly promising targets for cancer therapy, exemplified by the FDA's approval of venetoclax in 2016. Researchers have intensified their endeavors to develop analogs with improved pharmacokinetic and pharmacodynamic properties. This Patent Highlight showcases PROTAC compounds showcasing robust and specific degradation of BCL-2, offering potential applications in the treatment of cancer, autoimmune disorders, and diseases related to the immune system.
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :